Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-06-09 Declaration of Voting R…
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Sanofi: Information concerning the total number of voting rights and shares - May 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it concerns 'Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce...'. It provides a table detailing the 'Total number of issued shares' and the 'Number of real voting rights' as of a specific date (May 31, 2025). This content directly relates to the official declaration of voting rights and share structure, which aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not an AGM presentation, a full annual report (10-K), or a simple dividend notice.
2025-06-09 English
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers". It provides a table detailing the number of shares and voting rights as of a specific date (May 31, 2025). This type of mandatory disclosure regarding the total number of voting rights and shares, often published monthly or periodically in France, relates directly to the capital structure and shareholder rights. While it is a specific regulatory filing, it doesn't fit perfectly into the defined categories like 10-K, ER, or IR. It is a specific regulatory announcement concerning share capital and voting rights. Given the options, it is a specific regulatory disclosure. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory update concerning shares and voting rights, it is best classified as a general Regulatory Filing (RNS) or potentially related to Share Issue/Capital Change (SHA) if it were a change, but here it is a periodic statement. However, the content is highly specific to voting rights disclosure, which is a common regulatory requirement. Given the strict definitions, and noting that it is a formal regulatory update that doesn't fit the other specific financial reports, RNS is the most appropriate fallback for a specific, non-standard regulatory notice. The document is short and provides definitive data, not an announcement of a larger report.
2025-06-09 French
Communiqué de presse : Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de VRS
Regulatory Filings Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces operational updates regarding the accelerated global delivery of the drug Beyfortus ahead of the 2025-2026 RSV season. It includes quotes from an Executive VP, details on production capacity, regulatory updates (EU protection duration), and standard boilerplate sections like 'About Sanofi' and 'Forward-Looking Statements' (which references the 20-F filing). This format—a formal announcement of business/product news released to the public and media—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K or IR), nor a transcript (CT), nor a specific management discussion (MDA), and it is a formal announcement of operational news, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or a general Regulatory Filing (RNS). Given the content is primarily operational/product news rather than strictly financial results highlights, and it is a press release format, RNS is a strong candidate. However, press releases often accompany or precede formal earnings announcements. Since it is a detailed press release announcing strategic operational progress and product updates, and it is not explicitly an earnings report, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback for a non-standard, non-financial-specific announcement.
2025-06-09 French
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
Regulatory Filings Classification · 99% confidence The document is explicitly titled "Press Release" and contains forward-looking statements typical of such announcements, including contact information for Media Relations and Investor Relations. It discusses a product update (shipping acceleration for Beyfortus) and market positioning, which aligns with an initial announcement of operational or product news rather than a comprehensive financial report (10-K, IR) or a formal regulatory filing like a proxy statement or earnings release. Since it is a press release announcing business updates, and it doesn't fit the specific definitions for ER (Earnings Release), DIV (Dividend), or CAP (Financing), the most appropriate general category for a significant, non-financial-result-focused announcement is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered elsewhere, although 'Press Release' itself is not a defined code. Given the options, RNS is the best fit for a general, non-periodic, non-financial-result announcement.
2025-06-09 English
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 99% confidence The document is explicitly titled "Disclosure of trading in own shares" and details the purchase of Sanofi's own shares over a specific period (June 2nd to June 6th, 2025), including volume and weighted average price. This directly corresponds to the definition of a report concerning the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category.
2025-06-06 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document title is "Déclaration des transactions sur actions propres" (Declaration of transactions on own shares). The content details the volume and weighted average price of Sanofi's own shares transacted between June 2, 2025, and June 6, 2025, in compliance with share repurchase regulations. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which maps to the 'Transaction in Own Shares' category.
2025-06-06 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.